Aclaris Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Aclaris Therapeutics, Inc. (ACRS) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $10.33 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $10.33.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $10.55.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $12.72.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $13.75.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $10.33 10-Q · filed 2026-08-06 |
| 2026-03-31 | $10.55 10-Q · filed 2026-05-07 |
| 2025-12-31 | $12.72 10-K · filed 2026-02-26 |
| 2025-09-30 | $13.75 10-Q · filed 2025-11-06 |
| 2025-06-30 | $13.77 10-Q · filed 2025-08-07 |
| 2025-03-31 | $14.02 10-Q · filed 2025-05-08 |
| 2024-12-31 | $15.39 10-K · filed 2025-02-27 |
| 2024-09-30 | $15.40 10-Q · filed 2024-11-06 |
| 2024-06-30 | $15.74 10-Q · filed 2024-08-07 |
| 2024-03-31 | $16.24 10-Q · filed 2024-05-07 |
| 2023-12-31 | $16.55 10-K · filed 2024-02-27 |
| 2023-09-30 | $16.70 10-Q · filed 2023-11-06 |
| 2023-06-30 | $16.85 10-Q · filed 2023-08-07 |
| 2023-03-31 | $16.81 10-Q · filed 2023-05-08 |
| 2022-12-31 | $17.30 10-K · filed 2023-02-23 |
| 2022-09-30 | $17.35 10-Q · filed 2022-11-08 |
| 2022-06-30 | $18.26 10-Q · filed 2022-08-03 |
| 2022-03-31 | $17.92 10-Q · filed 2022-05-10 |
| 2021-12-31 | $17.86 10-K · filed 2022-02-24 |
| 2021-09-30 | $17.85 10-Q · filed 2021-11-02 |
| 2021-06-30 | $17.51 10-Q · filed 2021-08-05 |
| 2021-03-31 | $17.56 10-Q · filed 2021-05-07 |
| 2020-12-31 | $18.92 10-K · filed 2021-02-25 |
| 2020-09-30 | $18.84 10-Q · filed 2020-11-04 |
| 2020-06-30 | $19.16 10-Q · filed 2020-08-07 |
| 2020-03-31 | $19.47 10-Q · filed 2020-05-07 |
| 2019-12-31 | $19.48 10-K · filed 2020-02-25 |
| 2019-09-30 | $18.25 10-Q · filed 2019-11-07 |
| 2019-06-30 | $17.54 10-Q · filed 2019-08-08 |
| 2019-03-31 | $17.92 10-Q · filed 2019-05-08 |
| 2018-12-31 | $17.53 10-K · filed 2019-03-18 |
| 2018-09-30 | $15.70 10-Q · filed 2018-11-06 |
| 2018-06-30 | $15.25 10-Q · filed 2018-08-03 |
| 2018-03-31 | $15.33 10-Q · filed 2018-05-08 |
| 2017-12-31 | $15.56 10-K · filed 2018-03-12 |
| 2017-09-30 | $10.95 10-Q · filed 2017-11-07 |
| 2017-06-30 | $11.02 10-Q · filed 2017-08-08 |
| 2017-03-31 | $11.09 10-Q · filed 2017-05-09 |
| 2016-12-31 | $10.93 10-K · filed 2017-03-15 |
| 2016-09-30 | $5.54 10-Q · filed 2016-11-03 |
| 2016-06-30 | $1.36 10-Q · filed 2016-08-11 |
| 2016-03-31 | $1.27 10-Q · filed 2016-05-11 |
| 2015-12-31 | $1.19 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |